seproxetine

Seproxetine is a selective serotonin reuptake inhibitor (SSRI) and the S-enantiomer of norfluoxetine, which is the main active metabolite of fluoxetine. It was developed as an antidepressant by Eli Lilly but was never marketed due to concerns about cardiac side effects related to QT interval prolongation. Seproxetine acts primarily by inhibiting the sodium-dependent serotonin transporter (SLC6A4), thereby increasing synaptic serotonin levels. It also inhibits dopamine and noradrenaline transporters and has activity at 5-HT2A and 5-HT2C receptors. Compared to fluoxetine, it is more potent in stimulating neurosteroid synthesis relative to its SSRI activity[1][2][3][4].

Other names

seproxetine(S)-norfluoxetineseproxetinaseproxetine hydrochloride